Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
Not yet recruiting · NCT07160452 · Registry updated 2025-09-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, anemia, chronic kidney disease, chronic renal failure syndrome, hematologic disorder, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Phase 4 | 2025-09-12 | NCT07160452 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shaikh Zayed Hospital, Lahore | 4 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||